(e.g., doxorubicin, epirubicin, idarubicin, daunorubicin, mitoxantrone)
Cardio-oncological evaluation*, BNP or NT-proBNP and Troponin**
before cancer treatment begins
In patients with LVEF <40%, anthracyclines are not recommended unless there are no effective alternative cancer treatment options.
In patients with LVEF <50% but ≥40%, ACEi (or ARB) and/or BB are recommended before treatment.
In patients exposed to multiple cardiotoxic agents with a normal LVEF and cardiovascular risk factors, ACEi (or ARB) and/or BB may be considered.
In patients with advanced or metastatic breast cancer who have received a cumulative dose of >300 mg/m2 doxorubicin or >540 mg/m2 epirubicin and would benefit from continued anthracycline-based therapy, dexrazoxane can be considered.
Cumulative dose doxorubicin ≥250 mg/m2 or equivalent***
Cumulative dose doxorubicin <250 mg/m2 or equivalent***
before each cycle
Troponin** after each cycle (end of infusion)
Presence of any of the following risk factors:
age ≥ 65, mediastinal radiotherapy, previous cardiotoxic drugs, previous heart disease, ≥two risk factors (including smoking, hypertension, diabetes, dyslipidemia, chronic renal insufficiency, and obesity), baseline elevation of cardiac biomarkers
after each cycle (end of infusion)
CV symptoms/signs OR Troponin +
before the next cycle and tailored monitoring on case-by-case basis
Annual cardiovascular risk assessment
within the year after the end of cancer treatment, at years 1, 3, 5, and every 5 years thereafter
* A cardio-oncological evaluation will systematically include at least one visit with blood pressure, blood glucose, lipid profile, GFR calculation, ECG and trans-thoracic echocardiography (TTE). Measurements of global longitudinal strain and 3D LVEF (if feasible) are recommended with the same machine.
**Assays should be carried out by the same laboratory (same type of troponin, same method of measurement).
Troponin + if >99e percentile of the URL
***To obtain the doxorubicin equivalent dose, multiply the dose of the anthracylcine of interest by the following number:
1 for Doxorubicin
0.8 for Epirubicin
0.6 for Daunorubicin
10.5 for Mitoxantrone
5 for Idarubicin
ACE=angiotensin converting-enzyme inhibitor; ARB=angiotensin receptor blocker; BB=beta-blocker; LVEF=left ventricular ejection fraction